Contact

Head of Corporate Communications
T +49 (0) 6172 608-96008
pr-fre@fresenius.com

Documents

Text as PDF document (PDF, 26 KB)

Fresenius SE & Co. KGaA („Fresenius") plans to increase its voting interest in Fresenius Medical Care AG & Co. KGaA („FME") through the purchase of approximately 3.5 million ordinary shares.

The planned transaction shall be executed through share purchases, carried out from time to time, in a manner intended to have minimal impact on FME's share price on the stock exchange.

After maturity of the Mandatory Exchangeable Bond on August 14, 2011, Fresenius' current voting interest in FME is 30.3%. The exercise of FME stock options could, however, dilute Fresenius' interest to 29.3% mid-term.

The planned share purchase is meant to preserve a long-term voting interest in FME above 30%, maintaining the current ownership situation. Under applicable German law, if Fresenius' ownership were to fall below 30% and Fresenius purchased additional ordinary shares to bring its ownership above 30%, Fresenius would become obligated to offer to purchase all of FME's shares. Upon completion of the purchase of approximately 3.5 million ordinary shares, Fresenius' voting interest in FME would increase to approximately 31.5%.

Fresenius' position as general partner of FME requires ownership of at least 25% of FME's share capital.

The number of shares to be purchased corresponds to the XETRA trading volume of four to five average trading days.

Based on FME‘s current share price, the financing requirement for Fresenius is approximately €180 million. It shall be funded from cash flow and existing credit lines. Fresenius expects its incremental share in FME's net income to exceed its cost of financing the share purchase. The planned share purchase is therefore expected to be slightly accretive to Group net income. From today's perspective, Group Net Debt/EBITDA, including the effect of the planned share purchase, will stay below 3.0 in 2012.

Fresenius will provide details on the share purchase upon its completion.

Contact

Head of Corporate Communications
T +49 (0) 6172 608-96008
pr-fre@fresenius.com

Documents

Text as PDF document (PDF, 22 KB)

The Supervisory Board of Fresenius Kabi AG today announced changes in the Management Board of Fresenius Kabi. Effective March 1, 2012 Mats Henriksson, who serves as Member of the Management Board of Fresenius Kabi AG and President of the region Asia Pacific, will be promoted to Deputy Chairman of the Management Board of Fresenius Kabi AG. On January 1, 2013 Mats will succeed Rainer Baule as President and CEO of the Management Board of Fresenius Kabi AG. The appointment of Mats Henriksson is part of the company's succession plan to ensure a smooth transition of leadership.

Effective March 1, 2012 Thomas Mechtersheimer, who has been Senior Vice President for Fresenius Medical Care South Asia Pacific, will join the Fresenius Kabi AG Management Board as Deputy Member and will assume the position of President of region Asia Pacific. As of January 1, 2013 Thomas Mechtersheimer will become a full Member of the Management Board of Fresenius Kabi AG.

Since May 2001, Rainer Baule has been responsible for Fresenius Kabi, the second largest business segment within Fresenius, specialized in i.v. drugs, infusion therapies and clinical nutrition for the hospital and the outpatient care. Over the course of his tenure, company sales tripled and the geographic footprint expanded substantially. Today, Fresenius Kabi counts among the leading companies in its business segments worldwide. Rainer, who turned 63 this year, joined Fresenius in 1997 as President of the former Fresenius HemoCare business segment and Member of the Management Board of Fresenius, before he took over the responsibility for Fresenius Kabi.

Mats Henriksson joined the company in 1999 as Member of the Management Board of Fresenius Kabi AG. Since 2001, he has been President of the region Asia Pacific. Under his leadership, Fresenius Kabi has seen continued strong growth in this region, which is proven by No 1 or No 2 market positions in most countries in Asia Pacific.

Before joining the company, Mats held several controlling and finance positions at Pharmacia & Upjohn. At the end of 1998, Pharmacia & Upjohn divested its Clinical Nutrition business to Fresenius and Mats became the Chief Financial Officer and Member of the Management Board of Fresenius Kabi AG. He is a Swedish citizen and studied Business Administration and Economics at the Gothenburg School of Economics, Sweden.

Thomas Mechtersheimer has been Senior Vice President for Fresenius Medical Care South Asia Pacific since 2007 and currently reports directly to Roberto Fusté, Chief Executive Officer of Fresenius Medical Care Asia Pacific. Over the years, Thomas significantly contributed to the growth of Fresenius Medical Care in Asia and has a deep understanding of the Asian market dynamics. Thomas joined Fresenius in 1995 and has since held several executive positions within the Asian organization. Prior to joining Fresenius Medical Care, he worked in Industrial Automation and Special Machinery companies, both in Sales as well as in Technical Services. Thomas studied International Business at the Reutlingen University, Germany.

Rainer Baule, CEO and President of Fresenius Kabi AG, said: "We are very pleased with the appointments of Mats as my successor and Thomas as new Board Member of Fresenius Kabi. Mats has an outstanding track record of results-oriented performance and successful management experience within Fresenius Kabi. This qualifies him perfectly to serve as CEO and President of Fresenius Kabi. Thomas is an excellent successor of Mats. With his extensive experience and his profound knowledge of the Asian Pacific market, I am confident Thomas will make significant contributions to continue the successful growth of Fresenius Kabi's business in this region. I look forward to working closely with both."

Ulf Mark Schneider, CEO of Fresenius and Chairman of the Supervisory Board of Fresenius Kabi AG, said: "Under Rainer Baule's leadership, Fresenius Kabi has grown significantly and developed into a global player in health care. This is the right time to begin a smooth transition of leadership. We are pleased to elevate Mats Henriksson to the new position of Deputy Chairman of Fresenius Kabi's Management Board. Building on his significant accomplishments in Asia Pacific, this role will prepare Mats for succeeding Rainer in leading the company. Thomas Mechtersheimer brings valuable international management experience and a deep understanding of the health care market dynamics that will be essential for the continued growth of our Fresenius Kabi business in Asia Pacific. Both appointments come from within Fresenius and this reflects the strength and depth of our management team. I am confident that Rainer, Mats and Thomas, along with their colleagues of the Fresenius Kabi Management Board, will continue to successfully grow the company".

New Management Board of Fresenius Kabi by March 1, 2012:

Rainer Baule
Chief Executive Officer (CEO) and Chairman of the Management Board

Mats Henriksson
Deputy Chairman of the Management Board

Marc Crouton
President of Region West & South Europe, Latin America & Africa

John Ducker
President Region North America

Manfred M. Köhler
President of Region Central/Eastern Europe, Nordics & Middle East

Thomas Mechtersheimer
Deputy Member and President Region Asia Pacific

Dr. Michael Schönhofen
President Science, Production & Technology

Gerrit Steen
Chief Financial Officer

Contact

Head of Corporate Communications
T +49 (0) 6172 608-96008
pr-fre@fresenius.com

Documents

Text as PDF document (PDF, 25 KB)

HELIOS Kliniken GmbH, a subsidiary of Fresenius, has completed the acquisition of 51% of the share capital of Katholisches Klinikum Duisburg (KKD), following approval by the German antitrust authority. The other shareholders of KKD are local institutions related to the Catholic Church. HELIOS will fully consolidate KKD's sales and earnings as of January 1, 2012. The acquisition was announced in October 2011.

KKD operates a maximum care hospital with four locations in Duisburg and a total of 1,034 beds as well as a rehabilitation clinic with 220 beds. KKD also operates two nursing care facilities. In 2010, KKD's hospitals provided inpatient care for about 30,000 patients (thereof 26,500 in acute care). KKD has about 2,200 employees and achieved 2010 sales of approximately €134 million.

Contact

Head of Corporate Communications
T +49 (0) 6172 608-96008
pr-fre@fresenius.com

Documents

Text as PDF document (PDF, 26 KB)

Fresenius Medical Care AG & Co. KGaA ("the company"; Frankfurt Stock Exchange: FME / New York Stock Exchange: FMS), the world's largest provider of dialysis products and services, today announced revised outlook for revenue to be approximately 1.0% to 2.0% below the US-Dollar 13 billion benchmark. The impact on the revenue is predominately due to significant weakening of the Euro and other currencies against the US-Dollar in the fourth quarter of 2011. Nevertheless, the company continues to confirm its earnings after tax target in US-Dollar although expectations are that the net income attributable to the company will be at the low end of the target range of US-Dollar 1,070-1,090 million, principally due to the additional one-time costs incurred in 2011 related to acquisitions.

Ben Lipps, Chief Executive Officer and Chairman of the Management Board of Fresenius Medical Care: "The company is having another excellent year in 2011, meeting also the challenges of the reimbursement reform in the United States, growing our business substantially in all regions and managing the integration of a number of significant acquisitions."

Contact

Head of Corporate Communications
T +49 (0) 6172 608-96008
pr-fre@fresenius.com

Documents

Text as PDF document (PDF, 37 KB)

After a strong third quarter, Fresenius expects to achieve excellent fourth quarter earnings growth in 2011. In particular, Fresenius Kabi and Fresenius Helios have continued to perform strongly.

Therefore, Fresenius improves its 2011 earnings outlook slightly and now expects to achieve constant currency net income* growth of approximately 18%. Fresenius previously improved its earnings outlook of 15% to 18% constant currency growth to the upper half of this range on November 2, 2011.

Sales growth in constant currency is expected to just reach the targeted c. 6% as current sales at Fresenius Medical Care and Fresenius Vamed remain slightly below expectations. Fresenius Kabi and Fresenius Helios continued to see excellent sales growth and are fully on track to achieve their guidance.

*Net income attributable to Fresenius SE & Co. KGaA; adjusted for the effects of mark-to-market accounting of the Mandatory Exchangeable Bonds and the Contingent Value Rights related to the acquisition of APP Pharmaceuticals. Both are non-cash items.

Contact

Head of Corporate Communications
T +49 (0) 6172 608-96008
pr-fre@fresenius.com

Documents

Text as PDF document (PDF, 26 KB)

Fresenius Medical Care AG & Co. KGaA ("the company"; Frankfurt Stock Exchange: FME / New York Stock Exchange: FMS), the world's largest provider of dialysis products and services, is entering the dialysis services market in Ecuador. Effective December 1, the company has acquired eight private dialysis clinics which currently treat over 1,000 dialysis patients. The clinics are located in highly populated areas of Ecuador: Manabi province in the northwest, Guayaquil in the southwest, and the capital Quito. Fresenius Medical Care acquired them from an Ecuadorian family. The clinics will add around $17 million in annual revenue and are expected to be accretive to earnings in the first year after closing of the transaction. Both parties have agreed not to disclose the purchase price.

Fresenius Medical Care has also agreed to acquire Nefrocontrol S.A., its local distribution partner in Ecuador since 1992, from the same owners. This acquisition will add another $7.5 million in annual revenue.

Both acquisitions will significantly strengthen Fresenius Medical Care's position in the dialysis market in Ecuador – a country in which currently over 6,000 patients require regular dialysis treatment. The number of dialysis patients in Ecuador is growing more rapidly than in most Latin American countries. To meet this rising demand, Fresenius Medical Care plans to expand the capacity of the acquired clinics.

"As a vertically integrated provider, we're delighted to offer patients in Ecuador top-quality dialysis services and products from a single source," said Dr. Emanuele Gatti, chief executive officer for Europe, Latin America, the Middle East and Africa, and global chief strategist of Fresenius Medical Care. "We aim to further expand our presence in Ecuador in the medium to long term. Our main objective is to provide the growing number of dialysis patients in the country with the best treatment possible."

Contact

Head of Corporate Communications
T +49 (0) 6172 608-96008
pr-fre@fresenius.com

Documents

Text as PDF document (PDF, 27 KB)

Fresenius Medical Care AG & Co. KGaA (the "company" or "Fresenius Medical Care"; Frankfurt Stock Exchange: FME / New York Stock Exchange: FMS), the world's largest provider of dialysis products and services, today announced its intention to sell U.S. dollar and euro-denominated senior unsecured notes (together the "senior notes") of $1.2 billion and €250 million. The tranches will have a maturity between 7.5 and 10 years. Proceeds from the offerings are intended to be used for acquisitions, including the acquisition of Liberty Dialysis Holdings, Inc., to refinance indebtedness and for general corporate purposes.

The dollar-denominated senior notes will be issued by Fresenius Medical Care US Finance II, Inc. and the euro-denominated senior notes will be issued by FMC Finance VIII S.A. Both issuers are wholly owned subsidiaries of the company. The senior notes will be offered through a private placement to institutional investors and will be guaranteed jointly and severally by the company and its subsidiaries, Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care Deutschland GmbH.

The proposed offering will not be registered under the Securities Act of 1933. The senior notes will be offered in the U.S. to "qualified institutional buyers" (QIBs) pursuant to the exemption from registration under Rule 144A of the Securities Act, and in exempted "offshore transactions" pursuant to Regulation S under the Securities Act. The senior notes may not be offered or sold in the U.S. unless registered under the Securities Act or pursuant to an applicable exemption from registration requirements.

Application has been made for admission of the senior notes to trading on the regulated market of the Luxembourg Stock Exchange.

Contact

Head of Corporate Communications
T +49 (0) 6172 608-96008
pr-fre@fresenius.com

Documents

Text as PDF document (PDF, 28 KB)

Fresenius Medical Care AG & Co. KGaA (the "company" or "Fresenius Medical Care"; Frankfurt Stock Exchange: FME / New York Stock Exchange: FMS), the world's largest provider of dialysis products and services, successfully placed three tranches of U.S. dollar and euro-denominated senior unsecured notes (together the "senior notes"). Proceeds amounting to approximately $1.82 billion are intended to be used for acquisitions, including the acquisition of Liberty Dialysis Holdings, Inc., to refinance indebtedness and for general corporate purposes.

The coupon for the dollar-denominated senior notes in the principal amount of $800 million due 2019 will be 5.625% and the coupon for the dollar-denominated senior notes in the principal amount of $700 million due 2022 will be 5.875%. The coupon for the euro-denominated senior notes in the principal amount of €250 million due 2019 will be 5.25%. All tranches were issued at par.

Michael Brosnan, chief financial officer of the company, commented: "This is the largest placement of senior notes in the history of Fresenius Medical Care and an important step in the financing of our growth strategy. We are very pleased to have successfully completed this offering at favorable rates in an overall challenging market environment. We believe this demonstrates that investors continue to recognize our financial stability and sustainable financial strength."

The dollar-denominated senior notes were offered by Fresenius Medical Care US Finance II, Inc. and the euro-denominated senior notes were offered by FMC Finance VIII S.A. Both issuers are wholly-owned subsidiaries of the company. The senior notes were offered through a private placement to institutional investors and will be guaranteed jointly and severally by the company and its subsidiaries, Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care Deutschland GmbH.

The senior notes have not been registered under the Securities Act of 1933 as amended, but were offered to "qualified institutional buyers" (QIBs) in the U.S. pursuant to the exemption from registration provided by Rule 144A under the Securities Act and in exempted "offshore transactions" pursuant to Regulation S under the Securities Act. The senior notes may not be offered or sold in the U.S. unless registered under the Securities Act or pursuant to an applicable exemption from registration requirements.

Application has been made for admission of the senior notes to trading on the regulated market of the Luxembourg Stock Exchange.

Contact

Head of Corporate Communications
T +49 (0) 6172 608-96008
pr-fre@fresenius.com

Documents

Text as PDF document (PDF, 21 KB)

Fresenius has Germany's best career website, according to a new study published by the market research institute Potentialpark. The Fresenius career portal was ranked first place, followed by ThyssenKrupp and Deutsche Post DHL. For the first time, Potentialpark also ranked companies' overall online HR marketing activities, including aspects such as application tracking systems and mobile communication. In this ranking, Fresenius also achieved pole position.

Potentialpark has evaluated the career websites of German companies annually since 2002. This year, the institute surveyed around 30,000 students worldwide about their personal preferences regarding career sites. It also assessed the online activities of around 130 German companies based on over 100 different criteria. Last year, Fresenius was ranked fifth in the Potentialpark study.

"We've done a lot of work over the past two years to improve our career portal," explains Markus Olbert, Senior Vice President for Corporate Human Resources at Fresenius. "So we're pleased to receive this fantastic reward in recognition of our efforts. The Internet is an excellent way for us to present Fresenius as an attractive employer. Attracting the right talents to contribute to Fresenius' future growth is a central task for HR departments throughout the Group."

The Fresenius career portal can be found at http://career.fresenius.com or by following the links from other Fresenius sites.

Contact

Head of Corporate Communications
T +49 (0) 6172 608-96008
pr-fre@fresenius.com

Fresenius will continue the legal dispute concerning the payment of legal fees at the German Federal Court of Justice. The court granted Fresenius' complaint against the Frankfurt am Main Higher Regional Court's decision issued on February 15, 2011. The legal dispute concerns the time of payment of legal fees to a law firm, a partner of which was also a member of the Fresenius SE supervisory board. While the supervisory board approved the underlying mandate in advance, the related payments were approved retroactively. This practice is in accordance with the prevailing legal opinion regarding this technicality. However, the Higher Regional Court took the view that the payment should also only have been made after separate approval by the supervisory board.